Welcome to "The Poster!" To become a subscriber and start getting updates on new content, subscribe now!
In the News
Science & Technology | (Updated) Nanotechnology: Understanding the Tiny Particles That May Save a Life
Could nanotechnology—the study of tiny matter ranging in size from 1 to 200 nanometers—be the future of cancer treatment? Although it is a relatively new field in cancer research, nanotechnology is not new to everyday life. Have you ever thought about the tennis ball you’ve thrown with your dog at the park and wondered what it is made of? Nanotechnology is used to make the tennis ball stronger.
Health & Safety | (Updated) Fort Detrick Gate Hours Change Effective April 10
The Fort Detrick gate hours will change beginning Friday, April 10. The new hours were recently provided by the U.S. Army Garrison (USAG), Fort Detrick. NCI will continue to work with the USAG to address questions that may arise. Note that no changes have been made for facilities outside of the Fort Detrick campus (e.g., the Advanced Technology Research Facility).
Events | Spring Research Festival Set for May 4–7; Registration Deadline April 17
The 19th Annual Spring Research Festival (SRF), sponsored by the National Interagency Confederation for Biological Research (NICBR), will be held May 4–7, at the same location as last year: just off Porter Street, in the back parking lot of Building 1507 (Odom Fitness Center).
Science & Technology | (Updated) NCI Fiscal 2016 Bypass Budget Proposes $25 Million for Frederick National Lab
The additional funding requested for Frederick National Laboratory for Cancer Research (FNLCR) in the Fiscal 2016 Bypass Budget was $25 million, or approximately 3.5 percent of the total additional funding request of $715 million.
Science & Technology | FDA Approves Immunotherapy for a Cancer that Affects Infants and Children
The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.